Eli Lilly Releases Results On Latest Disease Modifying Therapeutic For Alzheimer's Disease, Highlighting Need For Cognetivity's CognICA Platform
Eli Lilly Releases Results On Latest Disease Modifying Therapeutic For Alzheimer's Disease, Highlighting Need For Cognetivity's CognICA Platform
禮來公司發佈阿爾茨海默氏病最新疾病改善療法的結果，強調對Cognitivity Cognica平臺的需求
The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage
該消息突出表明，迫切需要在早期階段對這種疾病進行更一致、更大規模的檢測
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - Cognetivity Neurosciences Ltd. (CSE:CGN) (OTCQB:CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") is pleased to note Eli Lilly & Co.'s results for its experimental drug for Alzheimer's disease, which demonstrated slowing the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. The drug, donanemab, slowed the disease by 35% over a year and a half in a trial of 1,182 patients with early-stage...
不列顛哥倫比亞省溫哥華--（Newsfile Corp.-2023 年 5 月 9 日）- 認知神經科學有限公司 (CSE: CGN) (OTCQB: CGNSF...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。